Tag Archives: Transition Therapeutics

July, 2016

• 1 July

  OPKO Health Acquires Transition Therapeutics

  

  MIAMI & TORONTO–(BUSINESS WIRE)– OPKO Health, Inc. (NASDAQ:OPK) and Transition Therapeutics Inc. (NASDAQ:TTHI, TSX:TTH) announce the signing of a definitive agreement under which OPKO will acquire Transition Therapeutics, a clinical stage biotechnology company. Under the terms of the agreement approved by the Boards of Directors of both companies, Transition Therapeutics …

  Share

  • Facebook
  • Twitter
  • LinkedIn

April, 2016

• 18 April

  Lilly Ends Development Deal for Transition Therapeutics’ Phase III Ready Diabetes Drug

  

  TORONTO, April 18, 2016 /PRNewswire/ – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) today announced that it has received notification that Eli Lilly and Co. (“Lilly”) will not elect to advance diabetes drug candidate, TT401 into Phase 3 development. Under the companies’ collaboration agreement, all TT401 …

  Share

  • Facebook
  • Twitter
  • LinkedIn